Sutton Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Sutton Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-80	Closed	-$1.37K	–	1159
2018 Q1	$1.37K	Hold	80	–	–	﹤0.01%	1028
2017 Q4	$1.52K	Hold	80	–	–	﹤0.01%	984
2017 Q3	$1.41K	Hold	80	–	–	﹤0.01%	980
2017 Q2	$2.66K	Hold	80	–	–	﹤0.01%	939
2017 Q1	$2.57K	Hold	80	–	–	﹤0.01%	919
2016 Q4	$2.9K	Hold	80	–	–	﹤0.01%	904
2016 Q3	$3.68K	Hold	80	–	–	﹤0.01%	874
2016 Q2	$4.02K	Hold	80	–	–	﹤0.01%	832
2016 Q1	$4.28K	Buy	+80	New	+$4.69K	﹤0.01%	787

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Sutton Wealth Advisors's TEVA Position: Q2 2018 in Review

Sutton Wealth Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2018, closing a stake of 80 shares — an estimated $1.37K sold.

Sutton Wealth Advisors first reported a position in TEVA in Q1 2016 and held it in 9 quarters. The position peaked at $4.28K in Q1 2016. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2018.

Sutton Wealth Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Sutton Wealth Advisors sold 80 Teva Pharmaceuticals shares in Q2 2018, an estimated $1.37K.
Sutton Wealth Advisors first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 9 quarters.
Sutton Wealth Advisors's Teva Pharmaceuticals position peaked at $4.28K in Q1 2016.
539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2018.

Based on Sutton Wealth Advisors's 13F filing for Q2 2018, filed 6 Nov 2023.